ArticleInternational journal of general medicine2026
Metabolic Endotypes for Dialysis Risk Stratification in Chronic Kidney Disease Stages G2-G4: A Pragmatic Cluster Analysis Using Routine Laboratory Tests.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chronic kidney disease (CKD) affects over 850 million people globally, but traditional staging based on eGFR and albuminuria fails to capture metabolic heterogeneity and divergent outcomes in CKD stages G2-G4 (15 < eGFR < 90 mL/min/1.73m Methods: This single-center retrospective cohort study included 400 CKD stages G2-G4 patients (2022-2024) from The Central Hospital of Wuhan. Nine routine biomarkers (estimated glomerular filtration rate [eGFR], uric acid, glucose, phosphate, parathyroid hormone [PTH], albumin, hemoglobin, D-dimer, total cholesterol) underwent robust preprocessing, followed by unsupervised K-means clustering. The nine input variables were selected a priori based on their established roles in core CKD pathophysiological pathways (CKD‑MBD, malnutrition‑inflammation‑anemia, and glycolipid‑uric acid dysregulation), grounding the clustering in biological mechanisms rather than purely empirical data‑driven reduction. Optimal clusters (K=4) were confirmed via multiple statistical metrics and clinical interpretability. Results: Four distinct metabolic endotypes emerged: 1) Inflammatory-hypercoagulable (high D-dimer, low albumin); 2) Severe CKD-MBD-anemia (lowest eGFR/hemoglobin, highest PTH); 3) Metabolically favorable (highest eGFR/albumin/hemoglobin, lowest D-dimer); 4) Glycolipid-uric acid dysregulation (high glucose/uric acid/phosphate). Dialysis rates differed drastically: 59.4% (Endotype 2), 46.7% (Endotype 4), 38.7% (Endotype 1), and 6.7% (Endotype 3) (all P<0.001). Multivariable logistic regression incorporating metabolic endotype, age, gender, and eGFR yielded a corrected AUC of 0.838 (95% CI: 0.763-0.915) for predicting dialysis initiation, with a sensitivity of 94.6% and specificity of 69.4%. Conclusion: This pragmatic approach, based on routinely available laboratory tests, suggests potential application value for risk stratification in clinical practice and provides a preliminary framework for future precision medicine research. However, given the single‑center retrospective design, its generalizability requires external validation in large‑scale prospective multi‑center cohorts before clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.